Chimeron Bio

Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.

The ChaESAR™/MultiPlex™ platform utilizes self-amplifying RNA (saRNA) to enable the direct, in-vivo delivery of large (up to 20kb), complex multi-gene therapeutic payloads with weeks-long expression and a non-viral safety profile.

Chimeron competes with companies developing in-vivo cell engineering (e.g., Umoja Biopharma, Ensoma) and next-gen RNA delivery platforms. Its differentiation lies in the combination of large multi-gene payload capacity and weeks-long expression using its proprietary saRNA technology, aiming to overcome limitations of viral vectors and standard LNPs.